[Production and clinical study of monoclonal antibodies against liver ferritin].
Monoclonal antibody (mAb.) against liver ferritin was produced by immunization of human liver ferritin. Using this mAb., an RPHA system for measurement of the serum ferritin level was established. This system had a good correlation coefficient (0.8625) with the RIA method and could measure levels of more than 2 ng/ml. The reactivity to heart ferritin in this RPHA system was not distinguished from that to liver ferritin. The positive rate in various conditions was as follows: 68.6% in pancreatic cancer, 59.1% in hepatoma, and 18% in healthy individuals. In pancreatic cancer and hepatoma, the serum ferritin levels were statistically higher than in healthy subjects or those with chronic pancreatitis.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D005260:Female; D005293:Ferritins / Q000097:blood / Q000276:immunology*; D006801:Humans; D008099:Liver / Q000032:analysis / Q000276:immunology*; D008297:Male; D051379:Mice; D010190:Pancreatic Neoplasms / Q000097:blood; D011863:Radioimmunoassay
D000911:Antibodies, Monoclonal; D005293:Ferritins